TCRX
TScan Therapeutics, Inc.
Biotechnology
Market Cap$162M
5Y Perf.-87.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TCRX vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.-12.4%
TCRX vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TCRX | TMO |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $162M | $175.76B |
| Revenue (TTM) | $8M | $45.20B |
| Net Income (TTM) | $-124M | $6.86B |
| Gross Margin | 81.7% | 39.4% |
| Operating Margin | -15.8% | 17.8% |
| Forward P/E | — | 19.0x |
| Total Debt | $94M | $40.85B |
| Cash & Equiv. | $152M | $9.86B |
TCRX vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TCRX
TMO
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| TScan Therapeutics,… (TCRX) | 100 | 12.9 | -87.1% |
| Thermo Fisher Scien… (TMO) | 100 | 87.6 | -12.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TCRX vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 5 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. TScan Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
TCRX
TScan Therapeutics, Inc.
The Growth Play
TCRX is the clearest fit if your priority is growth exposure.
- Rev growth 266.7%, EPS growth 12.3%, 3Y rev CAGR -8.6%
- 266.7% revenue growth vs TMO's 3.9%
Best for: growth exposure
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- 229.1% 10Y total return vs TCRX's -88.1%
- Lower volatility, beta 1.10, Low D/E 76.3%, current ratio 1.89x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TCRX | 266.7% revenue growth vs TMO's 3.9% |
| Quality / Margins | TMO | 15.2% margin vs TCRX's -15.2% |
| Stability / Safety | TMO | Beta 1.10 vs TCRX's 2.35, lower leverage |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TMO | +16.6% vs TCRX's -8.1% |
| Efficiency (ROA) | TMO | 6.4% ROA vs TCRX's -50.1%, ROIC 7.5% vs -90.7% |
TCRX vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
TCRX vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGTCRX
TCRXTScan Therapeutics, I…
1leads
TMOThermo Fisher Scienti…
4leads
6 Total Categories
CATEGORYLEADERvs TCRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TMO4/6
Valuation MetricsMultiples, price ratios, and targets
TCRX2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TMO5/6
Risk & VolatilityBeta, volatility, and downside exposure
TMO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TMO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 5542.9x TCRX's $8M. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to TCRX's -15.2%. On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TCRXTScan Therapeutic… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $8M | $45.2B |
| EBITDAEarnings before interest/tax | -$127M | $10.5B |
| Net IncomeAfter-tax profit | -$124M | $6.9B |
| Free Cash FlowCash after capex | -$125M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +81.7% | +39.4% |
| Operating MarginEBIT ÷ Revenue | -15.8% | +17.8% |
| Net MarginNet income ÷ Revenue | -15.2% | +15.2% |
| FCF MarginFCF ÷ Revenue | -15.3% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.4% | +11.3% |
TMO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
TCRX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | TCRXTScan Therapeutic… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $162M | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $104M | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.25x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | — | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 15.73x | 3.94x |
| Price / BookPrice ÷ Book value/share | 1.32x | 3.33x |
| Price / FCFMarket cap ÷ FCF | — | 27.93x |
TCRX leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-92 for TCRX. TMO carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to TCRX's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs TCRX's 2/9, reflecting solid financial health.
| Metric | TCRXTScan Therapeutic… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -91.9% | +13.2% |
| ROA (TTM)Return on assets | -50.1% | +6.4% |
| ROICReturn on invested capital | -90.7% | +7.5% |
| ROCEReturn on capital employed | -49.8% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | 0.76x | 0.76x |
| Net DebtTotal debt minus cash | -$58M | $31.0B |
| Cash & Equiv.Liquid assets | $152M | $9.9B |
| Total DebtShort + long-term debt | $94M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | -73.07x | 5.89x |
TMO leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TMO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $1,190 for TCRX. Over the past 12 months, TMO leads with a +16.6% total return vs TCRX's -8.1%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs TCRX's -17.8% — a key indicator of consistent wealth creation.
| Metric | TCRXTScan Therapeutic… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +22.5% | -20.1% |
| 1-Year ReturnPast 12 months | -8.1% | +16.6% |
| 3-Year ReturnCumulative with dividends | -44.4% | -11.9% |
| 5-Year ReturnCumulative with dividends | -88.1% | +2.1% |
| 10-Year ReturnCumulative with dividends | -88.1% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -17.8% | -4.2% |
TMO leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than TCRX's 2.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.4% from its 52-week high vs TCRX's 48.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TCRXTScan Therapeutic… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.35x | 1.10x |
| 52-Week HighHighest price in past year | $2.57 | $643.99 |
| 52-Week LowLowest price in past year | $0.88 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +48.6% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 53.9 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 903K | 1.9M |
TMO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TCRX as "Buy" and TMO as "Buy". Consensus price targets imply 500.0% upside for TCRX (target: $8) vs 38.4% for TMO (target: $655). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | TCRXTScan Therapeutic… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.50 | $654.67 |
| # AnalystsCovering analysts | 8 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
TMO leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TCRX leads in 1 (Valuation Metrics).
Best OverallThermo Fisher Scientific In… (TMO)Leads 4 of 6 categories
Loading custom metrics...
TCRX vs TMO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is TCRX or TMO a better buy right now?
For growth investors, TScan Therapeutics, Inc.
(TCRX) is the stronger pick with 266. 7% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate TScan Therapeutics, Inc. (TCRX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TCRX or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -88. 1% for TScan Therapeutics, Inc. (TCRX). Over 10 years, the gap is even starker: TMO returned +229. 1% versus TCRX's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TCRX or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus TScan Therapeutics, Inc. 's 2. 35β — meaning TCRX is approximately 115% more volatile than TMO relative to the S&P 500. On balance sheet safety, Thermo Fisher Scientific Inc. (TMO) carries a lower debt/equity ratio of 76% versus 76% for TScan Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TCRX or TMO?
By revenue growth (latest reported year), TScan Therapeutics, Inc.
(TCRX) is pulling ahead at 266. 7% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: TScan Therapeutics, Inc. grew EPS 12. 3% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TCRX or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus -1256. 8% for TScan Therapeutics, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -1315. 4% for TCRX. At the gross margin level — before operating expenses — TCRX leads at 72. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TCRX or TMO more undervalued right now?
Analyst consensus price targets imply the most upside for TCRX: 500.
0% to $7. 50.
07Which pays a better dividend — TCRX or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. TCRX does not pay a meaningful dividend and should not be held primarily for income.
08Is TCRX or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). TScan Therapeutics, Inc. (TCRX) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +229. 1%, TCRX: -88. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TCRX and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TCRX is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TCRX: -100.0% · TMO: 6.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.